Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00805740 · ClinicalTrials.gov registry record · Phase 3
An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Deep Tissue Infection Due To Candida
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 41
- Enrollment target
NCT00805740 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 41 participants.
The verdict
NCT00805740, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 41 participants
- Enrollment target
Study Summary
The purpose of this study is to gather information on the use of anidulafungin for the treatment of serious Candida infection. It is expected that anidulafungin will be at least as safe and as effective as the comparator drug, caspofungin.
Interventions
- DRUG Active anidulafungin
- DRUG Active Caspofungin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2009-04 |
| Est. Completion | 2012-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00805740
The ClinicalTrials.gov registry entry for NCT00805740 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Active anidulafungin is the first listed.
NCT00805740 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00805740 about?
NCT00805740 is a clinical study titled "An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Deep Tissue Infection Due To Candida". The purpose of this study is to gather information on the use of anidulafungin for the treatment of serious Candida infection. It is expected that anidulafungin will be at least as safe and as effective as the comparator drug, caspofungin.
What is the current status of trial NCT00805740?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 41 participants. The study started on 2009-04. Estimated completion is 2012-06.
What interventions are being tested in trial NCT00805740?
The interventions under investigation include: Active anidulafungin (DRUG), Active Caspofungin (DRUG).
Who is sponsoring clinical trial NCT00805740?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.